Member Info for hamila01

J.kemp - ‘it would be naive to assume it has no impact on IMM discussions’

It’s also naive to think big pharma will be scared off by what’s going on at Incanthera if the P140 science works. Likewise, they’re not buying Tim, they’re buying a platform that could make significant profits over the long term.

It’s about generating profits at the end of the day, so if big pharma has to hold its nose while dealing with Tim then that’s what it’ll do.

GLA genuine LTH’s!

Msuk - I trust Grok more than I do your TA.

GLA genuine LTH’s!

I’ve just asked the question on Grok whether autoimmune diseases are tricky to diagnose and it returned this:

**Yes, identifying autoimmune diseases is often quite complicated.** There are over 100 known autoimmune conditions (such as rheumatoid arthritis, lupus, Hashimoto's thyroiditis, multiple sclerosis, and type 1 diabetes), and diagnosis frequently involves delays, multiple specialists, and uncertainty.

### Why Diagnosis Is Challenging

Several factors make it difficult:

- **Nonspecific and overlapping symptoms**: Common early signs like fatigue, joint/muscle pain, low-grade fever, brain fog, rashes, or inflammation mimic many other conditions (infections, stress, fibromyalgia, or even normal aging). Symptoms often flare and remit (come and go), which complicates tracking.

- **No single definitive test**: Doctors rely on a combination of:

- Detailed medical history and physical exam.

- Blood tests (e.g., antinuclear antibody/ANA as a common screen, inflammatory markers like ESR/CRP, specific autoantibodies).

- Imaging (X-rays, MRI).

- Sometimes biopsies or other specialized tests.

Many patients are **"seronegative"** — they have the disease but test negative on standard antibody panels, requiring diagnosis based on clinical criteria and exclusion of other causes.

- **Variability across diseases and patients**: The same condition can present differently in different people, and patients can have more than one autoimmune disease (polyautoimmunity). Some conditions are easier to spot (e.g., certain thyroid diseases with clear hormone tests), while others like lupus or Sjögren's are notoriously tricky.

- **Time and specialist involvement**: Surveys show it often takes an average of **4+ years and visits to about 4 doctors** before a correct diagnosis. Primary care providers may not immediately consider rarer autoimmune issues.

### The Process Typically Involves

1. Ruling out more common explanations.

2. Looking for patterns in symptoms and family history (autoimmune diseases often run in families).

3. Targeted testing guided by a rheumatologist or other specialist.

Advances in testing and awareness help, but the process remains imperfect due to the underlying complexity of the immune system.

If you're experiencing persistent unexplained symptoms (e.g., ongoing fatigue + joint pain + rashes), keep a detailed symptom journal (including timing, triggers, and family history), see your doctor, and consider asking for a referral to a rheumatologist. Early diagnosis can make management much easier, even if the journey is frustrating. Consult a healthcare professional for personalized advice — this is not a substitute for medical care.

Look critically on what AI has generated for hallucinations, etc but certainly backs up what Rookie mentioned. It’s not impossible to diagnose but very challenging and any way to improve the diagnosis process has got to have value….

GLA genuine LTH’s!

Revd - I’m not faintly interested in being judge, jury and executioner and neither should you be given the role of forum moderator. I am interested in reasoned debate supported by evidence but don’t see why I or anyone else for that matter should be told to respect views that aren’t supported by evidence.

Still waiting for evidence on why the P140 deal has been shelved. And still waiting for someone to explain why the end of all discussions doesn’t warrant an RNS….

GLA genuine LTH’s!

Revd - Sorry, but not all views are valuable and to be respected - I’m thinking specifically about those views that are expressed with zero evidence to back up claims earlier like the P140 deal being shelved.

A poster (can’t remember who it was) wrote earlier that if that was true, IMM would need to issue an RNS. As they haven’t, discussions must still be going on.

So these two opposing views, one based on fact, the other unsubstantiated both have to be valued and respected?

GLA genuine LTH’s!

Silentmystic - Where's your evidence to support your 'p140 is shelved and all deals are off the shelf.' comment?

GLA genuine LTH's!

Spantrout - What a sad life you lead obsessing about a company you have little faith in......

GLA genuine LTH's!

Laura - Full respect and appreciate your posts reiterating the science and progress that IMM have made recently. However, I’d suggest dropping the £345 quote now. It was quite some time ago and the calculation doesn’t price in the increase in shares in circulation now.

Figures in the high £’s are unlikely in the medium (3-5 years) term and I really do think IMM will get taken out by big pharma long before the valuation increases based on royalties and market potential.

GLA genuine LTH’s!

Roger - ‘Very pleased I jumped ship at 5.85p albeit with a loss.’

For someone that doesn’t own shares, why are you here, boring everyone to death with the same old ‘Don’t trust Timmy liar’ schtick time and time again? We know what your view is but your posts are making you sound very sad and totally obsessive and to use one of your words, a stooge as well. Meanwhile a lot of us other stooges are here for the science…..

GLA genuine LTH’s!

Excellent points Gourd.

Agree totally on your point about the medical journal quality. IoW is definitely recommended as a holiday destination though.....

Provided the journal is highly respected then why would IMM (and more importantly the CNRS) open themselves up for ridicule by publishing? You've got to have a lot of confidence in the end product (which Dr Goudreau appears to have) to want to open it up to peer scrutiny before a deal is signed.....

Hopefully we'll look back at this in the future and see the publication as a complete master stroke by focusing interested parties to complete DD and submit offers for P140.

GLA genuine LTH's!

I stated September in my post but I should have written November.

GLA genuine LTH's!

Pension investor - Deals can easily take 6-12 months to negotiate.

One of my criticisms of Tim was his hyperbole in some of the interviews last year and most likely overly optimistic about deal timelines. But it’s also been mentioned that more parties came to the party after September so that would introduce delays to any deal being finalised. It’s interesting that the hyperbole and over optimism has been removed from his narrative so entirely possible that Ketan and/or other interested parties have asked him to be more restrained.

GLA genuine LTH’s!

Bootnk - Maybe there’s no need to spend money in effect showcasing a product that IMM already have interest in. Different matter perhaps in 12-18 months time when it comes to Kapiglucagon.

You’d be one of many to complain if IMM did go and yet you’re now complaining that they’re not attending….. Doesn’t matter what IMM does or doesn’t do when it comes to the critics….

GLA genuine LTH’s!

MrRSoul - I’ll take non attendance as a positive if IMM are already in discussions with a number of interested parties.

GLA genuine LTH’s!

Silentmystic - Deflection that time instead of misinformation.

GLA genuine LTH’s!

No silentmystic - more misinformation. Kapiglucagon won’t take a few years to enter phase 1…..

ImmuPharma PLC is accelerating the development of Kapiglucagon, a proprietary glucagon prodrug designed for type 1 diabetes, with an "accelerated" or "fast-track" approach supported by recent funding and a targeted 505(b)(2) regulatory pathway.

GLA genuine LTH’s!

I see it rather as industry networking. It helps with marketing the business and generating potential deals.

Dare say the naysayers will use another networking event as a deflection technique for avoiding the question about why they hang around here if they dislike Tim and don’t believe in the science…..

GLA genuine LTH’s!

Mystic Mike - The RNS’s state that Avion were progressing into phase 3. However, you specifically said Avion had no intention to pay for the trial.

The RNS’s you referred to don’t support your statement about Avion’s intentions. Circumstances may have changed that meant that it was no longer the right course of action for Avion to progress the trial at that time. Speculation on my part here but it might not have been Avion or Tim that paused the trial start but possibly the CNRS that called a halt. At best what you said sounds like some conspiracy theory that Avion are deliberately hampering IMM’s efforts in getting P140 to market. At worst it sounds like an extension of the normal line of attack that IMM management are scammers by adding Avion to the list as well.

And for balance I’ll state that I’d rather we didn’t have Avion’s US deal but at the time it was a necessary evil to keep IMM and P140 in the game.

GLA genuine LTH’s!

Mystic Mike - where’s your proof to say that ‘And they have never had any intension to pay £25m for a Phase 3 trial.’? That’s quite a big statement to make unless you have inside information to support such a comment.

Don’t you think IMM would have some standard legal clauses in the contract to cover a scenario where Avion decided not to progress the trial, thereby nullifying the agreement? Rights to Lupozor reverted back to IMM years ago on a previous deal when the partner was taken over by a rival. Clauses to cover breaches, takeovers, etc are common in pharma contracts and IMM I’m sure would address this area very carefully based on that previous experience.

GLA genuine LTH’s!

Musk - It’ll be a great feat when a deal hits…..

Patience is a virtue when it comes to investing.

GLA genuine LTH’s!